P01-011 – Colchicine compliance and amyloidosis

P01-011 – Colchicine compliance and amyloidosis

Results In 14 of the 26 patients, FMF and amyloidosis were diagnosed at the same time with a mean delay in diagnosis of 22 ±9.2 years. In the remaining 12, there was a mean delay of 9.6±8 years from the onset to the diagnosis of FMF and 23±9.6 years from the onset to the diagnosis of amyloidosis. These patients were on colchicine for a mean of 13±7.6 years after the diagnosis of FMF. Eight were...

P01-031 – Anakinra for colchicine resistant FMF

Methods We plan to include patients, agreeing with clinical and genetic diagnosis of FMF, who suffer from FMF attacks, at least once per month, in one of the sites commonly involved by FMF (Chest, abdomen, lower extremity large joints, and skin), despite treatment with colchicine 2 mg/ day or less (in case of colchicine intolerance). Involvement with other diseases relevant (vasculitis, spondyl...

Colchicine in systemic amyloidosis.

SIR, We read with interest the report by Scheinberg et al.' of DMSO and colchicine therapy in amyloid disease. The beneficial effects of colchicine on systemic amyloidosis have been suggested by other investigators.2We also have investigated the effect of colchicine on patients with primary (five patients), reactive (three patients), and familial Mediterranean fever (FMF) related secondary amyl...

Periodic peritonitis, amyloidosis and colchicine.

P01-036 – Systemic amyloidosis presenting with amyloidoma

Introduction Amyloidosis is a heterogeneous group of disorders characterized by extracellular deposition of unique protein fibrils. The least common presentation of an amyloid deposition is as a discrete mass called amyloidoma or amyloid tumor. It has been reported in many anatomic site including the respiratory, genitourinary, and gastrointestinal tracts, as well as internal viscera, the centr...